Show simple item record

dc.contributor.authorGirotti, Maria Romina
dc.contributor.authorLopes, F
dc.contributor.authorPreece, N
dc.contributor.authorNiculescu-Duvaz, D
dc.contributor.authorZambon, A
dc.contributor.authorDavies, L
dc.contributor.authorWhittaker, S
dc.contributor.authorSaturno, G
dc.contributor.authorViros, A
dc.contributor.authorPedersen, M
dc.contributor.authorSuijkerbuijk, B
dc.contributor.authorMenard, D
dc.contributor.authorMcLeary, R
dc.contributor.authorJohnson, L
dc.contributor.authorFish, L
dc.contributor.authorEjiama, S
dc.contributor.authorSanchez-Laorden, B
dc.contributor.authorHohloch, J
dc.contributor.authorCarragher, N
dc.contributor.authorMacleod, K
dc.contributor.authorAshton, Garry
dc.contributor.authorMarusiak, Anna A
dc.contributor.authorFusi, Alberto
dc.contributor.authorBrognard, John
dc.contributor.authorFrame, M
dc.contributor.authorLorigan, Paul C
dc.contributor.authorMarais, Richard
dc.contributor.authorSpringer, C
dc.date.accessioned2015-01-08T11:09:26Z
dc.date.available2015-01-08T11:09:26Z
dc.date.issued2014-12-10
dc.identifier.citationParadox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. 2014: Cancer Cellen
dc.identifier.issn1878-3686
dc.identifier.pmid25500121
dc.identifier.doi10.1016/j.ccell.2014.11.006
dc.identifier.urihttp://hdl.handle.net/10541/337935
dc.description.abstractBRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Cancer cellen
dc.titleParadox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.en
dc.typeArticleen
dc.contributor.departmentMolecular Oncology Group, Cancer Research UK Manchester Institute, Manchester M20 4BX,en
dc.identifier.journalCancer Cellen
html.description.abstractBRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs. Resistance is often mediated by pathway reactivation through receptor tyrosine kinase (RTK)/SRC-family kinase (SFK) signaling or mutant NRAS, which drive paradoxical reactivation of the pathway. We describe pan-RAF inhibitors (CCT196969, CCT241161) that also inhibit SFKs. These compounds do not drive paradoxical pathway activation and inhibit MEK/ERK in BRAF and NRAS mutant melanoma. They inhibit melanoma cells and patient-derived xenografts that are resistant to BRAF and BRAF/MEK inhibitors. Thus, paradox-breaking pan-RAF inhibitors that also inhibit SFKs could provide first-line treatment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistance.


Files in this item

This item appears in the following Collection(s)

Show simple item record